Penpulimab |
| Catalog No.GC66394 |
Penpulimab is an IgG1 backbone anti-PD-1 monoclonal antibody with antitumor activities.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2350298-92-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Penpulimab is an IgG1 backbone anti-PD-1 monoclonal antibody with antitumor activities[1].
Penpulimab demonstrates better stability and a lower level of host-cell protein residue compared with IgG4 backbone anti-PD-1 antibodies[1].
Penpulimab does not mediate complement-dependent cytotoxicity (CDC) or antibody-dependent cell-mediated cytotoxicity (ADCC) and induces no remarkable IL-6 and IL-8 release by activated macrophages[1].
Penpulimab exhibits slower binding off-rate for human PD-1 than Nivolumab (HY-P9903) and Pembrolizumab (HY-P9902)[1].
Penpulimab potentiates T cell activation via PD-1/PD-L1 blockade[1].
Penpulimab (5 mg/kg; i.p.; twice a week, 3weeks) inhibits tumor growth in mice[2].
| Animal Model: | MC38-hPD-L1 tumor-bearing B-hPD-1 humanized mouse model[2] |
| Dosage: | 5 mg/kg |
| Administration: | IP, twice a week, 3weeks |
| Result: | Showed moderate inhibition of tumor growth (tumor volume: 58.4% of control group). Treatment combined with anlotinib (1 mg/kg, every day, p.o) significantly decreased tumor volume to 36.5% of control group. |
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *